Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma

(MedPage Today) -- At the recent American Society of Hematology annual meeting, early data from the Mithic-FL1 Trial demonstrated impressive response rates with frontline mosunetuzumab (Lunsumio) in high-tumor-bulk follicular lymphoma, positioning...